Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310838 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Christian Salbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Registries, Anticoagulants, Stroke. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Daiichi Sankyo Europe.
Abstract (Originalsprache)
Background
The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.
Methods
This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.
Results
The risks for all-cause mortality (HR: 3.26, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Heidelberg, Germany.
ORCID-Profile: Christian Salbach, Barbara Ruth Milles, Moritz Biener
Förderung
- Bayer
- Daiichi Sankyo Europe
Zitieren
APA
Salbach, C., Milles, B. R., Hund, H., Biener, M., Mueller-Hennessen, M., Frey, N., Katus, H., Giannitsis, E., & Yildirim, M. (2024). Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry. PLOS ONE. https://doi.org/10.1371/journal.pone.0310838
Vancouver
Salbach C, Milles BR, Hund H, Biener M, Mueller-Hennessen M, Frey N, et al. Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry. PLOS ONE. 2024. doi:10.1371/journal.pone.0310838
BibTeX
@article{Salbach2024,
author = {Salbach, Christian and Milles, Barbara Ruth and Hund, Hauke and Biener, Moritz and Mueller-Hennessen, Matthias and Frey, Norbert and Katus, Hugo and Giannitsis, Evangelos and Yildirim, Mustafa},
title = {Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310838}
}
EUVIMED